Dr. Feng Wang got his Ph.D in structural biology/biochemistry at TAMU, where he worked on determination of structures of therapeutic target protein and structure-based inhibitor design. As a postdoctoral fellow, Dr. Wang worked with Professor Peter G. Schultz, a pioneer in chemical biology and biomedical research, at The Scripps Research Institute, La Jolla, California, where he identified a novel antibody scaffold from Bovine which is distinct from conventional antibody scaffold. The characterization of this novel antibody scaffold not only reveals a new mechanism of antibody evolution but also provides a new platform for antibody therapy development. In Calibr, Dr. Wang and his group continue to work on developing therapeutic antibody using the unique scaffold Dr. Wang has adopted in bovine. Dr. Wang has more than 40 publications, 7 patents and patent applications. His work is currently funded by Bill & Melinda Gates Foundation, Juvenile Diabetes Research Foundation (JDRF), and Merck & CO.